News

Number of news items returned: 141 to 160 records of 452

Nelson Resources extends closing of its Replacement Prospectus

22 February 2017

(15519 views)

   "Nelson Resources extends closing of its Replacement Prospectus   The Nelson Resources Limited (the Company, ASX: NES) Board is pleased to advise ...

Crowdfunding and other news - Funding Strategies Connect February 2017

20 February 2017

(15946 views)

Crowdfunding and other news - Funding Strategies Connect February 2017 Dear Readers, "Crowd-sourced equity funding bill to pass Senate" It looks like Australia ...

Crowd-sourced equity funding bill to pass Senate

16 February 2017

(14713 views)

 Crowd-sourced equity funding bill to pass Senate   "Retail investors will soon be able to buy up to $10,000 of equity in ...

Trustee Tailored Super Progresses In-depth Discussions

15 February 2017

(14533 views)

  "Trustee Tailored Super Progresses In-depth Discussions" "While the company (Tailored Superannuation Solutions) is maintaining strict confidentiality around businesses they are in ...

Nelson Resources - Investor Presentation, Road Show and Extension of Offer

03 February 2017

(15934 views)

    Nelson Resources - Investor Presentation, Road Show and Extension of Offer   Nelson Resources (ASX: NES) has today released an updated investor ...

Happy new year of the Rooster - Funding Strategies Connect January 2017

20 January 2017

(15717 views)

 Happy new year of the Rooster - Funding Strategies Connect January 2017 Dear Readers, I would like to wish you a healthy, ...

Nelson Resources Lodges Replacement Prospectus

18 January 2017

(16403 views)

  "The Nelson Resources Limited Board is pleased to advise that Nelson Resources Limited has lodged its Replacement Prospectus to raise ...

Director Briefing with Douglas Bucknell from Tailored Superannuation Solutions

17 January 2017

(15346 views)

  Please read the full briefing via the link below. For more information about Tailored Superannuation Solutions Ltd, please click here.  

"Australian Army Selects Ocular Robotics’ Immersive Telepresence System to be Trialed in Army Units in 2017"

17 January 2017

(15480 views)

  "Following from Ocular Robotics initial selection to demonstrate an Immersive Telepresence System at Army Innovation Day (AID16) in October 2016, ...

Opmantek reports bumper half year result

17 January 2017

(15575 views)

 OPMANTEK REPORTS BUMPER HALF YEAR RESULT " An increase in SaaS (software as a service) subscription contracts has seen Opmantek achieve their ...

Director Briefing with Laurence Baum from BioCube

19 December 2016

(16454 views)

  Please read the full briefing via the link below. For more information about The BioCube Corporation Ltd, please click here.  

"End of year super reforms surge in preparation for 2017"

15 December 2016

(16678 views)

  "End of year super reforms surge in preparation for 2017" "In the last month, the first public skirmishes of a reform ...

"The rebirth of crowd funding in Australia!"

15 December 2016

(16517 views)

" The rebirth of crowd funding in Australia!" " Introduction In December 2015, the Corporations Amendment (Crowd-sourced Funding) Bill 2015 (2015 Bill) was ...

"Turnbull government’s crowdfunding bill ‘flawed’ "

12 December 2016

(16372 views)

"Turnbull government’s crowdfunding bill ‘flawed’"    "The federal government’s proposed framework for equity crowdfunding is counter-productive to the aims of internet-enabled finance, ...

Director Briefing with Adam Schofield from Nelson Resources Limited

09 December 2016

(16984 views)

Please read the full briefing via the link below.  For more information about Nelson Resources Limited, please click here. 

With best wishes for the festive season - Funding Strategies Connect Dec 2016

07 December 2016

(14807 views)

With best wishes for the festive season - Funding Strategies Connect Dec 2016      Dear Readers,   In this, our final newsletter for 2016, ...

Tailoring to MySuper members to provide a 35+% improvement in retirement lifestyles

28 November 2016

(17430 views)

 Tailoring to MySuper members to provide a 35+% improvement in retirement lifestyles   "Isn’t it time the superannuation industry got real, started concentrating on ...

Tailored Superannuation Solutions Ltd presenting at Wholesale Investor Events

25 November 2016

(17352 views)

   Tailored Superannuation Solutions Ltd presenting at Wholesale Investor Events    Douglas Bucknell, Managing Director of Tailored Superannuation Solutions Ltd, has announced that ...

Nelson Resources Announce Additional Road Show Dates

25 November 2016

(16914 views)

  Nelson Resources Announce Additional Road Show Dates   The Nelson Resources team are in Sydney on Wednesday, 30th November and Thursday, 1st ...

The superannuation industry is ripe for change and disruption is here

24 November 2016

(16746 views)

" The superannuation industry is ripe for change and disruption is here" " The industry association ASFA, CEO Martin Fahy certainly thinks so ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625